The biology of the peroxisome proliferator-activated receptor system in the female reproductive tract

Current Pharmaceutical Design

Volumn 19, Issue 25, 2013, Pages 4641-4646

  Vélez, Leandro Martín ^a   Abruzzese, Giselle Adriana ^a   Motta, Alicia Beatriz ^a  

^a Centre de Estudios Farmacologicos y Botanicos   (Argentina)

Author keywords

Female reproductive tract; Fuel sensors; Infertility; Insulin resistance; Ovary; Peroxisome proliferator activated receptor (PPAR); Polycystic ovary syndrome; Prostaglandins; Uterus

Indexed keywords

5 (2,4 DIOXO 5 THIAZOLIDINYLMETHYL) 2 METHOXY N [4 (TRIFLUOROMETHYL)BENZYL]BENZAMIDE; BEZAFIBRATE; DNA; FIBRIC ACID DERIVATIVE; GLUCOSE; HETERODIMER; IMIGLITAZAR; INSULIN; INSULIN RECEPTOR; LEPTIN; LIPID; MURAGLITAZAR; NAVEGLITAZAR; NETOGLITAZONE; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLASMINOGEN ACTIVATOR; PROPIONIC ACID DERIVATIVE; PROTEINASE; RAGAGLITAZAR; RETINOID X RECEPTOR; ROSIGLITAZONE; TESAGLITAZAR; THIAZOLIDINE DERIVATIVE; TRANSCRIPTION FACTOR; UNINDEXED DRUG;

ANOVULATION; ARTICLE; CORPUS LUTEUM; DIABETES MELLITUS; ENDOMETRIUM; FEMALE GENITAL SYSTEM; FERTILITY; GAMETOGENESIS; GENE EXPRESSION; HYPOPHYSIS; HYPOPHYSIS GONAD SYSTEM; HYPOTHALAMUS; LIPOGENESIS; LUTEOLYSIS; METABOLISM; NIDATION; OBESITY; OOCYTE MATURATION; OVARY; OVARY POLYCYSTIC DISEASE; OVULATION; PLACENTA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; STEROIDOGENESIS;

FEMALE; GENITALIA, FEMALE; HUMANS; LIGANDS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS;

EID: 84881356255     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319250010     Document Type: Article

References (79)

1. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990; 347: 645-50.
2. Ferré, P The biology of peroxisome proliferator activated receptors. Diabetes 2004; 53: S43-S45.
3. Fernandez-Fernandez R, Martín AC, Navarro VM, et al. Novel signals for the integration of energy balance and reproduction. Mol Cel Endocrinol 2006; 254-255: 127-32.
4. Komar CM. Peroxisome proliferator-activated receptors (PPARs) and ovarian function-implications for regulating steroidogenesis, differentiation, and tissue remodeling. Reprod Biol Endocrinol 2005; 3: 41-55.
5. Huang JCh. The Role of peroxisome proliferator-activated receptors in the development and physiology of gametes and preimplantation embryos. PPAR Research 2008; doi: 10.1155/2008/732303.
6. Kersten S, Desvergne B, Wahli W. Roles of PPARS in health and disease. Nature 2000; 405: 421-4.
7. Lim H, Gupta A, Ma WG, et al. Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARα. Genes Dev 1999; 13: 1561-74.
8. Gupta RA, Wang D, Katkuri S, Wang H, Dey SK, DuBois RN. Activation of nuclear hormone receptor peroxisome proliferatoractivated receptor-γ accelerates intestinal adenoma growth. Nature Med 2004; 10: 245-7.
9. Gupta RA, Tan T, Krause K, et al. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor α in colorectal cancer. Proc Natl Acad Sci USA 2000; 97: 13275-80.
10. Di-Poi N, Michalik L, Tan NS, Desvergne B, Wahli W. The antiapoptotic role of PPAR contributes to efficient skin wound healing. J Steroid Biochem Mol Biol 2003; 85: 257-65.
11. Di-Poi N, CY Ng CY, Tan NS, et al. Epithelium-mesenchyme interactions control the activity of peroxisome proliferatoractivated receptor α/β during hair follicle development. Mol Cell Biol 2005; 25: 1696-712.
12. Liou JY, Lee S, Ghelani D, Matijevic-Aleksic N, Wu KK. Protection of endothelial survival by peroxisome proliferator-activated receptor-γ mediated 14-3-3 upregulation. Arterioscler Thromb Vasc Biol 2006; 26: 1481-7.
13. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20: 649-88.
14. Xu HE, Lambert MH, Montana VG, et al. Structural determinants of ligand binding selectivity between the peroxisome proliferatoractivated receptors. Proc Natl Acad Sci USA 2001; 98: 13919-24.
15. Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med 2004; 10: 355-61.
16. Clementi AH, Gaudy AM, van Rooijen N, Pierce RH, Mooney RA. Loss of Kupffer cells in diet-induced obesity is associated with increased hepatic steatosis, STAT3 signaling, and further decreases in insulin signaling. Biochim Biophys Acta 2009; 1792: 1062-72.
17. Pourcet B, Fruchart JC, Staels B, Glineur C. Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis. Expert Opin Emerg Drugs 2006; 11: 379-401.
18. Kasuga J, Makishima M, Hashimoto Y, Miyachi H. Design and synthesis of substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor alpha/delta dual agonists. Bioorg Med Chem Lett 2006; 16: 554-8.
19. Kasuga J, Yamasaki D, Araya Y, et al. Design, synthesis, and evaluation of a novel series of alpha-substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor (PPAR) alpha/delta dual agonists for the treatment of metabolic syndrome. Bioorg Med Chem 2006; 14: 8405-14.
20. Xu Y, Etgen GJ, Broderick CL, et al. Design and synthesis of dual peroxisome proliferator-activated receptors gamma and delta agonists as novel euglycemic agents with a reduced weight gain profile. J Med Chem 2006; 49: 5649-52.
21. Tenenbaum A, Motro M, Fisman EZ. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc Diabetol 2005; 4: 14-7.
22. Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 2005; 165: 1154-60.
23. Nagasawa T, Inada Y, Nakano S, et al. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine-and cholinedeficient diet. Eur J Pharmacol 2006; 536: 182-91.
24. Heaney AP, Fernando M, Melmed S. PPAR-gamma receptor ligands: novel therapy for pituitary adenomas. J Clin Invest 2003; 111: 1381-8.
25. Mouihate A, Boisse L, Pittman QJ. A novel antipyretic action of 15-deoxy-delta12,14-prostaglandin J2 in the rat brain. J Neurosc 2004; 24: 1312-08.
26. Wiesner G, Morash BA, Ur E, Wilkinson M. Food restriction regulates adipose-specific cytokines in pituitary gland but not in hypothalamus. J Endocrinol 2004; 180: R1-6.
27. Yang J, Chen L, Zhang X, et al. PPARs and female reproduction: evidence from genetically manipulated mice. PPAR Res 2008; 723243.
28. Froment P, Gizard F, Defever D, Staels B, Dupont J, Monget P. Peroxisome proliferator-activated receptors in reproductive tissues: from gametogenesis to parturition. J Endocrinol 2006; 189: 199-209.
29. Huang JC, Goldsby JS, Arbab F, Melhem Z, Aleksic N, Wu KK. Oviduct prostacyclin functions as a paracrine factor to augment the development of embryos. Hum Reprod 2004; 19: 2907-12.
30. Huang C, Wun WS, Goldsby JS, Wun IC, Noorhasan D, Wu KK. Stimulation of embryo hatching and implantation by prostacyclin and peroxisome proliferator-activated receptor activation: implication in IVF. Hum Reprod 2007; 22: 807-14.
31. Wang Y, Wen S, Mooney B, Behr B, Polan ML. Phospholipase A2 and cyclooxygenase gene expression in human preimplantation embryos. J Clin Endocrinol Metab 2002; 87: 2629-34.
32. Huang JC, Wun WSA, Goldsby JS, Matijevic-Aleksic N, Wu KK. Cyclooxygenase-2-derived endogenous prostacyclin enhances mouse embryo hatching. Hum Reprod 2004; 19: 2900-6.
33. Mohan M, Ryder S, Claypool PL, Geisert RD, Malayer JR. Analysis of gene expression in the bovine blastocyst produced in vitro using suppression-subtractive hybridization. Biol Reprod 2002; 67: 447-53.
34. Díaz M, Bassols J, López-Bermejo A, Gómez-Roig MD, de Zegher F, Ibáñez L. Placental expression of peroxisome proliferatoractivated receptor (PPAR): relation to placental and fetal growth. J Clin Endocrinol Metab 2012; 97: E1468-E1472.
35. Fournier T, Tsatsaris V, Handschuh K, Evain-Brion D. PPARs and the placenta. Placenta 2007; 28: 65-76.
36. Cutando A, Gil-Montoya JÁ. The dental patient with hemostatic disorders. A review of hemostasia physiopathology for dental professionals. Med Oral 1999; 4: 485-93.
37. Asami-Miyagishi R, Iseki S, Usui M, Uchida K, Kubo H, Morita I. Expression and function of PPAR in rat placental development. Biochem Biophys Res Com 2004; 315: 497-501.
38. Bogacka I, Bogacki M, Boruszewska D, Wasielak M. Expression of peroxisome proliferator activated receptor (PPAR) genes in porcine endometrium exposed in vitro to IL-6 and INF. Reprod Biol; 2012; 12: 157-70.
39. McKinnon B, Bersinger NA, Mueller MD. Peroxisome proliferating activating receptor gamma-independent attenuation of interleukin 6 and interleukin 8 secretion from primary endometrial stromal cells by thiazolidinediones. Fertil Steril 2012; 97: 657-64.
40. Elia EM, Pustovrh C, Amalfi S, Devoto L, Motta AB. Link between metformin and the peroxisome proliferator-activated receptor pathway in the uterine tissue of hyperandrogenized prepubertal mice. Fertil Steril 2011; 30: 2534-7.
41. Mendez M, LaPointe. MC PPARgamma inhibition of cyclooxygenase-2, PGE2 synthase, and inducible nitric oxide synthase in cardiac myocytes. Hypertension 2003; 42: 844-50.
42. Paria BC, Lim H, Wang XN, Liehr J, Das SK, Dey SK. Coordination of differential effects of primary estrogen and catecholestrogen on two distinct targets mediates embryo implantation in the mouse. Endocrinology 1998; 139: 5235-46.
43. Lee SS, Pineau T, Drago J, et al. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol 1995; 15: 3012-22.
44. Peters JM, Lee SS, Li W, et al. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta). Mol Cell Biol 2000; 20: 5119-28.
45. Peters JM, Lee SS, Li W, et al. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta). Mol Cell Biol 2002; 20: 5119-28.
46. Froment P, Fabre S, Dupont J, et al. Expression and functional role of peroxisome proliferator-activated receptor-gamma in ovarian folliculogenesis in the sheep. Biol Reprod 2003; 69: 1665-74.
47. Komar CM, Braissant O, Wahli W, Curry TE Jr. Expression and localization of PPARs in the rat ovary during follicular development and the periovulatory period. Endocrinology 2001; 142: 4831-8.
48. Faut M, Elia EM, Parborell F, Cugnata NM, Tesone M, Motta AB. Peroxisome proliferator-activated receptor gamma and early folliculogenesis during an acute hyperandrogenism condition. Fertil Steril 2011, 95: 333-7.
49. Amalfi S, Velez LM, Heber MF, et al. Prenatal hyperandrogenization induces metabolic and endocrine alterations which depend on the levels of testosterone exposure. PLoS One 2012; 7: e37658.
50. Jablonka-Shariff A, Ravi S, Beltsos AN, Murphy LL, Olson LM. Abnormal estrous cyclicity after disruption of endothelial and inducible nitric oxide synthase in mice. Biol Reprod 1999; 61: 171-7.
51. Estevez A, Tognetti T, Luchetti CG, Sander V, Motta AB. Sequence of interleukin 1beta actions on corpus luteum regression: relationship with inducible cyclooxygenase and nitric oxide synthase expression. Reproduction 2003; 126: 639-45.
52. Belkacemi L, Desai M, Nelson DM, Ross MG. Altered mitochondrial apoptotic pathway in placentas from undernourished rat gestations. Am J Physiol Regul Integr Comp Physiol 2011; 301: R1599-615.
53. Fergus P, McCarthy, Sascha Drewlo, et al. Evidence implicating peroxisome proliferator-activated receptor-in the pathogenesis of preeclampsia. Hypertension 2011; 58: 882-7.
54. Nickkho-Amiry M, McVey R, Holland C. Peroxisome proliferatoractivated receptors modulate proliferation and angiogenesis in human endometrial carcinoma. Mol Cancer Res 2012; 10: 441-53.
55. Cui Y, Miyoshi K, Claudio E, et al. Loss of the peroxisome proliferation-activated receptor (PPAR) does not affect mammary development and propensity for tumor formation but leads to reduced fertility. J Biol Chem 2002; 277: 17830-5.
56. Cammas L, Reinaud P, Bordas N, Dubois O, Germain G, Charpigny G. Developmental regulation of prostacyclin synthase and prostacyclin receptors in the ovine uterus and conceptus during the peri-implantation period. Reproduction 2006; 131: 917-27.
57. Wheeler-Jones C, Abu-Ghazaleh R, Cospedal R, Houliston RA, Martin J, Zachary I. Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42/p44 mitogen-activated protein kinase. FEBS Let 1997; 420: 28-32.
58. Murohara T, Horowitz JR, Silver M, et al. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation 1998; 97: 99-107.
59. Nadra K, Anghel SI, Joye E, et al. Differentiation of trophoblast giant cells and their metabolic functions are dependent on peroxisome proliferator-activated receptor α/β. Mol Cell Biol 2006; 26: 3266-81.
60. Barak Y, Liao D, He W, et al. Effects of peroxisome proliferatoractivated receptor on placentation, adiposity, and colorectal cancer. Proc Natl Acad Sci USA 2002; 303-8.
61. Schoppee PD, Garmey JC, Veldhuis JD. Putative activation of the peroxisome proliferator-activated receptor gamma impairs androgen and enhances progesterone biosynthesis in primary cultures of porcine theca cells. Biol Reprod 2002; 66: 190-8.
62. Gasic S, Nagamani M, Green A, Urban RJ. Troglitazone is a competitive inhibitor of 3 beta-hydroxysteroid dehydrogenase enzyme in the ovary. Am J Obst Gynecol 2001; 184: 575-9.
63. Mu YM, Yanase T, Nishi Y, et al. Insulin sensitizer, troglitazone, directly inhibits aromatase activity in human ovarian granulosa cells. Bioch Bioph Res Com 2000; 271: 710-3.
64. Lovekamp-Swan T, Chaffin CL. The peroxisome proliferatoractivated receptor gamma ligand troglitazone induces apoptosis and p53 in rat granulosa cells. Mol Cell Endocrinol 2005; 233: 15-24.
65. Banerjee J, Komar CM. Effects of luteinizing hormone on peroxisome proliferator-activated receptor in the rat ovary before and after the gonadotropin surge. Reproduction 2006; 131: 93-101.
66. Minge CE, Ryan NK, Hoek KH, Robker RL, Norman RJ. Troglitazone regulates peroxisome proliferator-activated receptors and inducible nitric oxide synthase in murine ovarian macrophages. Biol Reprod 2006; 74: 153-60.
67. Margalit O, Wang D, DuBois RN. PPAR agonists target aromataase via both PGE2 and BRCA1. Cancer Prev Res 2012; 1169-72.
68. Kadowaki T and Yamauchi. Adiponectin and adiponectin receptors. Endocr Rev 2005; 26: 439-51.
69. Ledoux S, Campos DB, Lopes FL, Dobias-Goff M, Palin MF, Murphy BD. Adiponectin induces preovulatory changes in ovarian follicular cells. Endocrinology 2006; 11: 5178-86.
70. Dupont J, Chabrolle Ch, Ramé Ch, Tosca L, Coyral-Castel S. Role of the peroxisome proliferator-activated receptors, adenosine monophosphate-activated kinase, and adiponectin in the ovary. PPAR Res 2008; 2008: 176275. doi: 10.1155/2008/176275.
71. Van Itallie TB. Health implications of overweight and obesity in the United State. Ann Int Med 1985; 103: 983-8.
72. Spieglelman BM, Flier JS. Adipogenesis and obesity: rounding out the big picture. Cell 1996; 87: 377-89.
73. Cho MC, Lee K, Paik SG, Yoon DY. Peroxisome proliferatorsactivated receptor (PPAR) modulators and metabolic disorders. PPAR Res. 2008; 2008: 679137. doi: 10.1155/2008/679137.
74. Yu S, Rao S, Reddy JK. Peroxisome proliferators-activated receptors, fatty acid oxidation, steatohepatitis and hepatocarcinogenesis. Curr Mol Med 2003; 3: 561-72.
75. Schmidt A, Endo N, Rutledge SJ, Vogel R, Shinar D, Rodan GA. Identification of a new member of the steroid hormone receptor superfamily that is activated by a proxisome proliferators and fatty acids. Mol Endocrinol 1992; 6: 1634-41.
76. Abbott DH. Developmental origin of polycystic ovary syndrome-A hypothesis. J Endocrinol 2003; 174: 1-5.
77. Diamanti-Kandarakis E, Spritzer PM, Sir-Petermann T, Motta AB. Insulin resistance and polycystic ovary syndrome through life. Curr Pharm Des. 2012; 18: 5569-76.
78. Rizzo M, Longo RA, Guastella E, Rini GB, Carmina E. Assessing cardiovascular risk in Mediterranean women with polycystic ovary syndrome. J Endocrinol Invest 2011; 34: 422-6.
79. Heber MF, Ferreira SR, Vélez LM, Motta AB. Prenatal hyperandrogenism and lipid profile during different age stages: an experimental study. Fertil Steril 2012; 1. doi: pii: S0015-0282(12)02317-5. 10.1016/j.fertnstert.2012.10.017. [Epub ahead of print]